G-protein-coupled receptors and pulmonary arterial hypertension (PAH)

The role of G protein-coupled receptors (GPCRs) in pulmonary arterial hypertension (PAH) is well recognized. GPCRs receptor agonists/antagonists aiming to offset the imbalance between vasoconstrictor/vasodilators seen in PAH constitute the basis of many currently used therapies. Implication of these receptors in PAH could be extended as our understanding of this vascular disease now goes beyond vascular tone, toward a proliferative vascular remodeling in which inflammation plays a prominent role. The breadth and depth of the GPCRs biology calls for a fresh look into their role in a complex disease like PAH that remains deadly and in urgent need for effective therapies.